The global mRNA vaccine market is expected to grow at a CAGR of 16.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing prevalence of infectious diseases and cancer globally. The increasing number of new cases and deaths due to cancer is expected to drive the demand for mRNA vaccines in the coming years.
The global mRNA vaccine market by type is segmented into standardization of cancer treatment MRNA vaccine, individualized cancer treatment MRNA vaccine, infectious disease treatment MRNA vaccine, and infection prevention MRNA vaccine. The standardization of cancer treatment MRNA vaccines segment accounted for a major share in 2018 owing to its ability in treating various types of cancers such as breast, lung, prostate etc, which are prevalent across different regions globally.
Infectious disease treatment MRNA vaccines accounted for a significant share in 2018 owing to their ability in preventing infections caused by viruses such as influenza virus or HIV virus that are prevalent across different regions globally.
- The global population is growing and aging, which will increase the demand for vaccines.
- The emergence of new infectious diseases such as Ebola and Zika will increase the demand for vaccines.
- The increasing number of people living with chronic conditions such as diabetes, cancer, and heart disease will also increase the demand for vaccines to prevent these diseases from progressing or recurring.
- Advances in vaccine technology are making it possible to develop more effective vaccines that can be used against a wider range of diseases than ever before, which will also drive up demand for these products in the future.
- Increasing awareness about vaccine safety issues has led some parents to refuse vaccinations for their children, which could lead to an increased risk of outbreaks among unvaccinated populations.
Industry Growth Insights published a new data on “mRNA Vaccine Market”. The research report is titled “mRNA Vaccine Market research by Types (Standardization Of Cancer Treatment MRNA Vaccine, Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, Infection Prevention MRNA Vaccine), By Applications (Infectious Disease, Cancer, Other), By Players/Companies Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology”.
Scope Of The Report
Report Attributes
Report Details
Report Title
mRNA Vaccine Market Research Report
By Type
Standardization Of Cancer Treatment MRNA Vaccine, Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, Infection Prevention MRNA Vaccine
By Application
Infectious Disease, Cancer, Other
By Companies
Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global mRNA Vaccine Market Report Segments:
The global mRNA Vaccine market is segmented on the basis of:
Types
Standardization Of Cancer Treatment MRNA Vaccine, Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, Infection Prevention MRNA Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Infectious Disease, Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Moderna Therapeutics
- CureVac
- Translate Bio
- BioNTech
- Sangamo Therapeutics
- Argos Therapeutics
- In-Cell-Art
- eTheRNA
- Ethris
- Tiba Biotechnology
Highlights of The mRNA Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Standardization Of Cancer Treatment MRNA Vaccine
- Individualized Cancer Treatment MRNA Vaccine
- Infectious Disease Treatment MRNA Vaccine
- Infection Prevention MRNA Vaccine
- By Application:
- Infectious Disease
- Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the mRNA Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
mRNA vaccine is a type of vaccine that uses pieces of messenger RNA (mRNA) from a virus or disease to help the body build immunity. This type of vaccine works best when it is given before exposure to the virus or disease.
Some of the major companies in the mrna vaccine market are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology.
The mrna vaccine market is expected to grow at a compound annual growth rate of 16.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. mRNA Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. mRNA Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. mRNA Vaccine Market - Supply Chain
4.5. Global mRNA Vaccine Market Forecast
4.5.1. mRNA Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. mRNA Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. mRNA Vaccine Market Absolute $ Opportunity
5. Global mRNA Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. mRNA Vaccine Market Size and Volume Forecast by Type
5.3.1. Standardization Of Cancer Treatment MRNA Vaccine
5.3.2. Individualized Cancer Treatment MRNA Vaccine
5.3.3. Infectious Disease Treatment MRNA Vaccine
5.3.4. Infection Prevention MRNA Vaccine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global mRNA Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. mRNA Vaccine Market Size and Volume Forecast by Application
6.3.1. Infectious Disease
6.3.2. Cancer
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global mRNA Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. mRNA Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global mRNA Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. mRNA Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global mRNA Vaccine Demand Share Forecast, 2019-2026
9. North America mRNA Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America mRNA Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America mRNA Vaccine Market Size and Volume Forecast by Application
9.4.1. Infectious Disease
9.4.2. Cancer
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America mRNA Vaccine Market Size and Volume Forecast by Type
9.7.1. Standardization Of Cancer Treatment MRNA Vaccine
9.7.2. Individualized Cancer Treatment MRNA Vaccine
9.7.3. Infectious Disease Treatment MRNA Vaccine
9.7.4. Infection Prevention MRNA Vaccine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America mRNA Vaccine Demand Share Forecast, 2019-2026
10. Latin America mRNA Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America mRNA Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America mRNA Vaccine Market Size and Volume Forecast by Application
10.4.1. Infectious Disease
10.4.2. Cancer
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America mRNA Vaccine Market Size and Volume Forecast by Type
10.7.1. Standardization Of Cancer Treatment MRNA Vaccine
10.7.2. Individualized Cancer Treatment MRNA Vaccine
10.7.3. Infectious Disease Treatment MRNA Vaccine
10.7.4. Infection Prevention MRNA Vaccine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America mRNA Vaccine Demand Share Forecast, 2019-2026
11. Europe mRNA Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe mRNA Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe mRNA Vaccine Market Size and Volume Forecast by Application
11.4.1. Infectious Disease
11.4.2. Cancer
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe mRNA Vaccine Market Size and Volume Forecast by Type
11.7.1. Standardization Of Cancer Treatment MRNA Vaccine
11.7.2. Individualized Cancer Treatment MRNA Vaccine
11.7.3. Infectious Disease Treatment MRNA Vaccine
11.7.4. Infection Prevention MRNA Vaccine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe mRNA Vaccine Demand Share, 2019-2026
12. Asia Pacific mRNA Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific mRNA Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific mRNA Vaccine Market Size and Volume Forecast by Application
12.4.1. Infectious Disease
12.4.2. Cancer
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific mRNA Vaccine Market Size and Volume Forecast by Type
12.7.1. Standardization Of Cancer Treatment MRNA Vaccine
12.7.2. Individualized Cancer Treatment MRNA Vaccine
12.7.3. Infectious Disease Treatment MRNA Vaccine
12.7.4. Infection Prevention MRNA Vaccine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific mRNA Vaccine Demand Share, 2019-2026
13. Middle East & Africa mRNA Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa mRNA Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa mRNA Vaccine Market Size and Volume Forecast by Application
13.4.1. Infectious Disease
13.4.2. Cancer
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa mRNA Vaccine Market Size and Volume Forecast by Type
13.7.1. Standardization Of Cancer Treatment MRNA Vaccine
13.7.2. Individualized Cancer Treatment MRNA Vaccine
13.7.3. Infectious Disease Treatment MRNA Vaccine
13.7.4. Infection Prevention MRNA Vaccine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa mRNA Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global mRNA Vaccine Market: Market Share Analysis
14.2. mRNA Vaccine Distributors and Customers
14.3. mRNA Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Moderna Therapeutics
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. CureVac
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Translate Bio
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. BioNTech
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sangamo Therapeutics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Argos Therapeutics
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. In-Cell-Art
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. eTheRNA
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Ethris
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Tiba Biotechnology
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
